Moderna completes FDA submission for booster dose targeting Omicron BA.4, BA.5

Article content

Moderna Inc said on Tuesday it

has completed its submission to the U.S. Food and Drug

Article content

Administration for the emergency use authorization of its

bivalent COVID-19 booster vaccine tailored against the BA.4 and

BA.5 subvariants of Omicron.

(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)

Source link

Comments are closed.